Synthetic biology’s malaria promises could backfire
October 30, 2013
Claims about the benefits of a biotech project to make artemisinin are overblown, says Claire Marris. In April, a consortium led by the global health NGO PATH — and comprising the University of California, Berkeley, synthetic biology company Amyris and pharmaceutical firm Sanofi — announced the first industrial production of ‘semi-synthetic artemisinin’. (Sci Dev Net)
